Vitamin D-dependent rickets type II: extreme end organ resistance to 1,25-dihydroxy vitamin D3 in a patient without alopecia
- PMID: 3024987
- DOI: 10.1007/BF00439245
Vitamin D-dependent rickets type II: extreme end organ resistance to 1,25-dihydroxy vitamin D3 in a patient without alopecia
Abstract
Vitamin D-dependent rickets type II (VDDR II) is a rare syndrome resulting in severe rickets and is resistant to treatment with vitamin D and its derivatives. Patient with this disease, who are frequently the children of consanguinous marriages, present with elevated circulating concentrations of 1,25-dihydroxy vitamin D, the active metabolite of vitamin D, and in vitro studies have indicated a failure of intracellular binding of the hormone. Alopecia has been noted in many of these patients and it has been suggested that this feature may indicate a more marked resistance to treatment. However we describe a 3-year-old boy with this disease who, although having normal hair growth, displayed extreme resistance to treatment with active vitamin D metabolites. In vitro studies of skin fibroblasts disclosed not only an absence of hormone binding or 1,25(OH)2D3-induced 24-hydroxylase activity but reduced metabolism of 1,25(OH)2D3 itself. In this child, treatment with exogenous 1,25-dihydroxy vitamin D3 at doses of up to 24 micrograms/day, which increased the circulating concentration of the metabolite to greater than 100 times the normal adult mean, failed to alleviate his condition and he died at the age of 39 months. This would therefore suggest that absence of alopecia, in this condition, cannot be regarded as a constant predictive sign of a lesser resistance and of responsiveness to Vitamin D treatment.
Similar articles
-
Two siblings with vitamin-D-dependent rickets type II: no recurrence of rickets for 14 years after cessation of therapy.Eur J Pediatr. 1989 Oct;149(1):54-7. doi: 10.1007/BF02024336. Eur J Pediatr. 1989. PMID: 2558018
-
Prenatal diagnosis of vitamin D-dependent rickets, type II: response to 1,25-dihydroxyvitamin D in amniotic fluid cells and fetal tissues.J Clin Endocrinol Metab. 1990 Oct;71(4):937-43. doi: 10.1210/jcem-71-4-937. J Clin Endocrinol Metab. 1990. PMID: 2169482
-
Impaired stimulation of 25-hydroxyvitamin D-24-hydroxylase in fibroblasts from a patient with vitamin D-dependent rickets, type II. A form of receptor-positive resistance to 1,25-dihydroxyvitamin D3.J Clin Invest. 1983 Oct;72(4):1190-9. doi: 10.1172/JCI111074. J Clin Invest. 1983. PMID: 6313754 Free PMC article.
-
The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).Clin Endocrinol (Oxf). 1993 Aug;39(2):229-37. doi: 10.1111/j.1365-2265.1993.tb01779.x. Clin Endocrinol (Oxf). 1993. PMID: 8396512 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction.Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7498-503. doi: 10.1073/pnas.131029498. Proc Natl Acad Sci U S A. 2001. PMID: 11416220 Free PMC article.
-
Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3.J Clin Invest. 1993 Jul;92(1):12-6. doi: 10.1172/JCI116539. J Clin Invest. 1993. PMID: 8392085 Free PMC article.
-
Intra-atrial calcium infusions, growth, and development in end organ resistance to vitamin D.Arch Dis Child. 1993 Dec;69(6):689-92. doi: 10.1136/adc.69.6.689. Arch Dis Child. 1993. PMID: 8285784 Free PMC article.
-
Clinical and biochemical findings in parents of children with vitamin D-dependent rickets Type II.J Inherit Metab Dis. 1991;14(2):231-40. doi: 10.1007/BF01800596. J Inherit Metab Dis. 1991. PMID: 1653381
-
Two siblings with vitamin-D-dependent rickets type II: no recurrence of rickets for 14 years after cessation of therapy.Eur J Pediatr. 1989 Oct;149(1):54-7. doi: 10.1007/BF02024336. Eur J Pediatr. 1989. PMID: 2558018